Literature DB >> 272218

Hallucinogenic N-methylated indolealkylamines in the cerebrospinal fluid of psychiatric and control populations.

L Corbett, S T Christian, R D Morin, F Benington, J R Smythies.   

Abstract

The incidence and quantities of dimethyltryptamine and O-methylbufotenine were studied in the cerebrospinal fluid of patients suffering acute schizophrenic illnesses and in surgical and neurological control groups. Some schizophrenic patients have higher levels of both amines than do controls, though the differences in distribution did not reach statistical significance in the sample studied. The gas-chromatographic technique used is sensitive at the low picogram level.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 272218     DOI: 10.1192/bjp.132.2.139

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  8 in total

1.  Naloxone enhancement of DMT and LSD-25 induced suppression of food-rewarded bar pressing behavior in the rat.

Authors:  D Ruffing; B Kovacic; S Demetriou; E F Domino
Journal:  Psychopharmacology (Berl)       Date:  1979-04-25       Impact factor: 4.530

2.  Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter.

Authors:  Nicholas V Cozzi; Anupama Gopalakrishnan; Lyndsey L Anderson; Joel T Feih; Alexander T Shulgin; Paul F Daley; Arnold E Ruoho
Journal:  J Neural Transm (Vienna)       Date:  2009-09-12       Impact factor: 3.575

Review 3.  The role of serotonin in schizophrenia: an overview of the nomenclature, distribution and alterations of serotonin receptors in the central nervous system.

Authors:  D C Ohuoha; T M Hyde; J E Kleinman
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 4.  N, N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past, Present, and Future Research to Determine Its Role and Function.

Authors:  Steven A Barker
Journal:  Front Neurosci       Date:  2018-08-06       Impact factor: 4.677

Review 5.  A narrative synthesis of research with 5-MeO-DMT.

Authors:  Anna O Ermakova; Fiona Dunbar; James Rucker; Matthew W Johnson
Journal:  J Psychopharmacol       Date:  2021-10-19       Impact factor: 4.153

Review 6.  The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT).

Authors:  Johannes T Reckweg; Malin V Uthaug; Attila Szabo; Alan K Davis; Rafael Lancelotta; Natasha L Mason; Johannes G Ramaekers
Journal:  J Neurochem       Date:  2022-03-08       Impact factor: 5.546

7.  Noncompetitive inhibition of indolethylamine-N-methyltransferase by N,N-dimethyltryptamine and N,N-dimethylaminopropyltryptamine.

Authors:  Uyen B Chu; Sevahn K Vorperian; Kenneth Satyshur; Kelsey Eickstaedt; Nicholas V Cozzi; Timur Mavlyutov; Abdol R Hajipour; Arnold E Ruoho
Journal:  Biochemistry       Date:  2014-04-28       Impact factor: 3.162

Review 8.  Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT.

Authors:  Steven A Barker
Journal:  Psychopharmacology (Berl)       Date:  2022-01-22       Impact factor: 4.415

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.